AstraZeneca PLC (NASDAQ:AZN) is one of the best long term low volatility stocks to invest in. AstraZeneca PLC (NASDAQ:AZN) announced on January 30 that it is bolstering its weight management portfolio ...
AstraZeneca is handing $1.2 billion in upfront cash to CSPC Pharmaceuticals for the ex-China rights to the biopharma’s ...
By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related ...
AstraZeneca AZN announced that it has entered into a new strategic collaboration with China-based CSPC Pharmaceutical to ...
The deal, which involves up to eight “next-generation” weight loss medications and could be worth more than $18 billion, ...
AstraZeneca entered a strategic collaboration with CSPC Pharmaceuticals to expand its weight management and metabolic disease ...
AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals: Cambridge, UK Saturday, January 31, 2026, 09:00 Hrs [IST] AstraZene ...
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...
AstraZeneca's full-year 2025 results are due on 10 February. Learn what investors should watch including Tagrisso sales, ...
(RTTNews) - Jacobio Pharma (1167.HK) announced that it has entered into a strategic agreement with AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) for its proprietary Pan-KRAS inhibitor, JAB-23E73. Under the ...